Sertraline fails to improve symptoms of depression in kidney disease patients

A 12‐week double‐blind, placebo‐controlled trial has found that the antidepressant sertraline did not result in significant improvement in depressive symptoms in patients with chronic kidney disease not involving dialysis. The study is believed to be the largest randomized trial of a commonly used selective serotonin reuptake inhibitor (SSRI) for treatment of major depression in this chronically ill population, a group that is highly susceptible to developing depression.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: What's New in Research Source Type: research